SCHEMBL3024248

SCHEMBL3024248

CCOC(=O)C1CN2C=C(C)N1CC2

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 1/20 0.40
FDFT1 P37268 1/20 0.37
CACNA1A O00555 1/20 0.37
CACNA2D1 P54289 1/20 0.37
CACNB1 Q02641 1/20 0.37
KDM4E B2RXH2 5/20 0.36
TSHR P16473 3/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
ATM Q13315 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 2/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020130 0.84 ALDH1A1 (0.37) ALDH1A1KMT2A
SCHEMBL3007661 0.84 CHRM2 (0.34) ALDH1A1LMNAKDM4EPOLBSMN1; SMN2
SCHEMBL3009541 0.75 ALDH1A1 (0.39) ALDH1A1LMNAKMT2ACACNA1ACACNA2D1
SCHEMBL3018295 0.73 ALDH1A1 (0.40) ALDH1A1LMNAKMT2ACACNA1ACACNA2D1
SCHEMBL3020249 0.72 NLRP3 (0.33)
SCHEMBL3020784 0.72 CHRM2 (0.35)
SCHEMBL3014343 0.71 ALDH1A1 (0.41) ALDH1A1LMNAKMT2ACACNA1ACACNA2D1
SCHEMBL3007851 0.71 KDM4E (0.37) ALDH1A1KMT2AKDM4ETSHRPOLB
SCHEMBL3016719 0.70 ALDH1A1 (0.38) ALDH1A1LMNAKMT2ACACNA1ACACNA2D1
SCHEMBL3019564 0.70 ALDH1A1 (0.38) ALDH1A1LMNAKMT2ACACNA1ACACNA2D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES BASF SE (DE) 2010-08-12 US disclosed
EP-2197882-A2 METHOD FOR PRODUCING TEDA DERIVATIVES Basf Se (DE) 2010-06-23 EP disclosed
WO-2009030649-A2 METHOD FOR PRODUCING TEDA DERIVATIVES BASF SE (DE) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204438-A1 METHOD FOR PRODUCING TEDA DERIVATIVES TES, TRRAP, NAAA ALDH1A1 720/4885LMNA 2940/4885KMT2A 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.